Nektar Therapeutics
NKTR
$0.7955
$0.05487.40%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 20.94% | 2.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 20.94% | 2.70% | |||
| Cost of Revenue | 79.86% | -54.47% | |||
| Gross Profit | 7.66% | 43.20% | |||
| SG&A Expenses | -9.61% | -7.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.82% | -2.59% | |||
| Operating Income | 28.04% | 5.99% | |||
| Income Before Tax | 118.90% | 29.19% | |||
| Income Tax Expenses | -2,977.78% | -80.43% | |||
| Earnings from Continuing Operations | 119.59% | 29.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 119.59% | 29.23% | |||
| EBIT | 28.04% | 5.99% | |||
| EBITDA | 26.89% | 4.91% | |||
| EPS Basic | 119.54% | 29.36% | |||
| Normalized Basic EPS | 13.67% | 5.39% | |||
| EPS Diluted | 119.20% | 29.36% | |||
| Normalized Diluted EPS | 15.20% | 5.39% | |||
| Average Basic Shares Outstanding | 0.23% | 0.20% | |||
| Average Diluted Shares Outstanding | 2.08% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||